Rodyti straipsnį

Pjautuvinių ląstelių liga (vaikai)

Anemijos gydymas

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (atsiveria naujas langas)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Šaltinis‎: Lancet Haematol. 2023 ;10(4):e261-71.

Kodas‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (atsiveria naujas langas)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (atsiveria naujas langas)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Šaltinis‎: Acta Haematol 1995;94(3):128-34.

Kodas‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (atsiveria naujas langas)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (atsiveria naujas langas)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Šaltinis‎: Haematologica 2006;91(8):1076-83.

Kodas‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (atsiveria naujas langas)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (atsiveria naujas langas)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Šaltinis‎: J Obstet Gynaecol 2007;27(1):82-3.

Kodas‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (atsiveria naujas langas)